Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action supports our ambitious Target Zero campaign — an initiative that aims to achieve zero days between Health Canada’s regulatory approval of a drug and our reimbursement recommendation to participating public drug plans.
A new evidence report from Canada’s Drug Agency identifies key factors that influence the ability of older adults in Canada to age in place and the systematic factors to consider when implementing initiatives that can allow people to age at home or in the community.
Current consultation status: Open
Consultation period: July 11, 2024, to September 11, 2024
Canada’s Drug Agency is developing pan-Canadian guidance to support decision-making related to newborn screening. This work is being led by our Newborn Screening Advisory Panel and supports the Government of Canada’s National Strategy for Drugs for Rare Diseases.
Canada’s Drug Agency is advancing our commitment to building meaningful relationships with patient communities by establishing a new Patient Member role on our Board of Directors. Through our open call for nominations, we are seeking a dedicated and experienced individual who will bring new perspectives to our table.
Canada’s Drug Agency is announcing recent and upcoming changes to the leadership of our Canadian Drug Expert Committee (CDEC), pan-Canadian Oncology Drug Review Expert Review Committee (pERC), and Patient and Community Advisory Committee (PCAC).
Dr. Peter Jamieson has been appointed incoming Chair of CDEC, Dr. Catherine Moltzan has been appointed incoming Chair of pERC, and Beth Kidd was appointed for a 7-month term as the Acting Chair of the PCAC on March 1, 2024.
Canada’s Drug Agency is launching a new 1-year learning period in our Scientific Advice program that will expand the type of guidance we offer to drug manufacturers to include those that are seeking advice after a “do not reimburse” recommendation is issued for their product.